❌

Normal view

Received — 18 September 2026 ⏭

Artificial Intelligence-Driven Multiomics and Clinical Investigation Identify Macrophage Migration Inhibitory Factor as a Pan-Cancer Biomarker

✇(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
By: Fengsen Liu · Yu Ping · Miaomiao Li · Kaiyuan Guo · Lei Zhang · Peng Wu · Yijun Tian · Jinyan Liu · Yi Zhang
17 September 2026 at 18:00

Phenomics. 2026 May 20;6(3):213-229. doi: 10.1007/s43657-026-00322-4. eCollection 2026 Jun.

ABSTRACT

Early cancer detection remains challenging due to the lack of reliable pan-cancer screening methods, particularly blood-based biomarkers. Using a novel three-tiered validation framework combining artificial intelligence (AI)-powered literature mining of 180,000 PubMed articles (1950-2024), multiomics integration across major databases, and extensive clinical validation, we identified macrophage migration inhibitory factor (MIF) as a promising blood-based biomarker for pan-cancer detection. Multiomics analysis revealed consistent MIF upregulation across 21 cancer types at the transcriptional level and across 12 cancer types at the protein level. Clinical validation in independent cohorts (n = 4,269) showed that serum MIF protein levels discriminated effectively between cancer patients and healthy controls (median AUC = 0.994) and between cancer and benign conditions (median AUC = 0.881). Notably, comparative analyses showed that MIF demonstrated superior or comparable performance to established cancer-specific markers, including AFP for hepatocellular carcinoma (MIF AUC = 0.885 vs. AFP AUC: 0.744-0.887) and CA125 for ovarian cancer (MIF AUC = 0.831 vs. CA125 AUC: 0.58-0.71). Meta-analysis of 28 cohorts (n = 5,347) confirmed the diagnostic efficacy of MIF (pooled AUC: 0.782). This cost-effective, blood-based ELISA approach establishes MIF as a valuable tool for broad applications in cancer screening.

SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at https://doi.org/10.1007/s43657-026-00322-4.

PMID:42750739 | PMC:PMC13578188 | DOI:10.1007/s43657-026-00322-4

Received — 10 September 2026 ⏭

Early stage nonsmall cell lung cancer: Toward a risk-adaptive paradigm in the era of biologic precision

✇Omics In Lung
By: Chaoqi Zhang · Xuanyu Gu · Pan Wang · Dongyu Li · Guochao Zhang · Ting Wang · Peng Wu · Wei Rao · Shan Muhammad · Binghua Tan · Yun Che · Mobai Zhu · Qilin Qiao · Fanbo Lai · Bohui Zhao · Kailun Fei · Yue Wu · Zhihui Zhang · Min Dai · Wanqing Chen · Yawei Zhang · Nan Bi · Jie Wang · Jie He
9 September 2026 at 18:00

CA Cancer J Clin. 2026 Sep-Oct;76(5):e70100. doi: 10.3322/caac.70100.

ABSTRACT

The clinical landscape of early stage nonsmall cell lung cancer is at transformative crossroads. Driven by the widespread adoption of low-dose computed tomography screening, the frequent detection of ground-glass opacities, and a rising incidence among never-smokers, the diagnostic center of gravity has shifted toward earlier, potentially curable disease. This shift has been accompanied by equally important therapeutic advances, including parenchyma-sparing surgical techniques, minimally invasive platforms enhanced by digital navigation, and the transformative integration of perioperative immunotherapy and targeted agents. Concurrently, noninvasive monitoring approaches, such as liquid biopsy, have emerged as powerful tools to guide precision management. Despite this progress, substantial barriers to achieving a universal cure persist. Clinicians continue to face uncertainty in the management of ground-glass opacities, the anatomy-based TNM staging system fails to capture the biologic heterogeneity of early tumors, and global disparities in access to innovation remain unresolved. To address these challenges, the authors propose a shift toward a risk-adaptive management paradigm that harnesses artificial intelligence-driven analytics and multi-omics profiling to tailor treatment intensity according to each patient's biologic risk. Such an approach would enable appropriate escalation for high-risk individuals while permitting safe de-escalation for those at low risk. This holistic, lifespan-oriented strategy must be embraced to deliver equitable and durable cures for patients with early stage nonsmall cell lung cancer.

PMID:42713910 | PMC:PMC13555834 | DOI:10.3322/caac.70100

Early stage nonsmall cell lung cancer: Toward a risk-adaptive paradigm in the era of biologic precision

✇(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
By: Chaoqi Zhang · Xuanyu Gu · Pan Wang · Dongyu Li · Guochao Zhang · Ting Wang · Peng Wu · Wei Rao · Shan Muhammad · Binghua Tan · Yun Che · Mobai Zhu · Qilin Qiao · Fanbo Lai · Bohui Zhao · Kailun Fei · Yue Wu · Zhihui Zhang · Min Dai · Wanqing Chen · Yawei Zhang · Nan Bi · Jie Wang · Jie He
9 September 2026 at 18:00

CA Cancer J Clin. 2026 Sep-Oct;76(5):e70100. doi: 10.3322/caac.70100.

ABSTRACT

The clinical landscape of early stage nonsmall cell lung cancer is at transformative crossroads. Driven by the widespread adoption of low-dose computed tomography screening, the frequent detection of ground-glass opacities, and a rising incidence among never-smokers, the diagnostic center of gravity has shifted toward earlier, potentially curable disease. This shift has been accompanied by equally important therapeutic advances, including parenchyma-sparing surgical techniques, minimally invasive platforms enhanced by digital navigation, and the transformative integration of perioperative immunotherapy and targeted agents. Concurrently, noninvasive monitoring approaches, such as liquid biopsy, have emerged as powerful tools to guide precision management. Despite this progress, substantial barriers to achieving a universal cure persist. Clinicians continue to face uncertainty in the management of ground-glass opacities, the anatomy-based TNM staging system fails to capture the biologic heterogeneity of early tumors, and global disparities in access to innovation remain unresolved. To address these challenges, the authors propose a shift toward a risk-adaptive management paradigm that harnesses artificial intelligence-driven analytics and multi-omics profiling to tailor treatment intensity according to each patient's biologic risk. Such an approach would enable appropriate escalation for high-risk individuals while permitting safe de-escalation for those at low risk. This holistic, lifespan-oriented strategy must be embraced to deliver equitable and durable cures for patients with early stage nonsmall cell lung cancer.

PMID:42713910 | DOI:10.3322/caac.70100

Received — 17 March 2026 ⏭

ESG-Bench: Benchmarking Long-Context ESG Reports for Hallucination Mitigation

✇cs.AI, q-bio.NC updates on arXiv.org
By: Siqi Sun · Ben Peng Wu · Mali Jin · Peizhen Bai · Hanpei Zhang · Xingyi Song
16 March 2026 at 12:00
arXiv:2603.13154v1 Announce Type: cross Abstract: As corporate responsibility increasingly incorporates environmental, social, and governance (ESG) criteria, ESG reporting is becoming a legal requirement in many regions and a key channel for documenting sustainability practices and assessing firms' long-term and ethical performance. However, the length and complexity of ESG disclosures make them difficult to interpret and automate the analysis reliably. To support scalable and trustworthy analysis, this paper introduces ESG-Bench, a benchmark dataset for ESG report understanding and hallucination mitigation in large language models (LLMs). ESG-Bench contains human-annotated question-answer (QA) pairs grounded in real-world ESG report contexts, with fine-grained labels indicating whether model outputs are factually supported or hallucinated. Framing ESG report analysis as a QA task with verifiability constraints enables systematic evaluation of LLMs' ability to extract and reason over ESG content and provides a new use case: mitigating hallucinations in socially sensitive, compliance-critical settings. We design task-specific Chain-of-Thought (CoT) prompting strategies and fine-tune multiple state-of-the-art LLMs on ESG-Bench using CoT-annotated rationales. Our experiments show that these CoT-based methods substantially outperform standard prompting and direct fine-tuning in reducing hallucinations, and that the gains transfer to existing QA benchmarks beyond the ESG domain.
Received — 11 March 2026 ⏭

Video-EM: Event-Centric Episodic Memory for Long-Form Video Understanding

✇cs.AI, q-bio.NC updates on arXiv.org
By: Yun Wang · Long Zhang · Jingren Liu · Jiaqi Yan · Zhanjie Zhang · Jiahao Zheng · Ao Ma · Run Ling · Xun Yang · Dapeng Wu · Xiangyu Chen · Xuelong Li
10 March 2026 at 12:00
arXiv:2508.09486v2 Announce Type: replace-cross Abstract: Video Large Language Models (Video-LLMs) have shown strong video understanding, yet their application to long-form videos remains constrained by limited context windows. A common workaround is to compress long videos into a handful of representative frames via retrieval or summarization. However, most existing pipelines score frames in isolation, implicitly assuming that frame-level saliency is sufficient for downstream reasoning. This often yields redundant selections, fragmented temporal evidence, and weakened narrative grounding for long-form video question answering. We present \textbf{Video-EM}, a training-free, event-centric episodic memory framework that reframes long-form VideoQA as \emph{episodic event construction} followed by \emph{memory refinement}. Instead of treating retrieved keyframes as independent visuals, Video-EM employs an LLM as an active memory agent to orchestrate off-the-shelf tools: it first localizes query-relevant moments via multi-grained semantic matching, then groups and segments them into temporally coherent events, and finally encodes each event as a grounded episodic memory with explicit temporal indices and spatio-temporal cues (capturing \emph{when}, \emph{where}, \emph{what}, and involved entities). To further suppress verbosity and noise from imperfect upstream signals, Video-EM integrates a reasoning-driven self-reflection loop that iteratively verifies evidence sufficiency and cross-event consistency, removes redundancy, and adaptively adjusts event granularity. The outcome is a compact yet reliable \emph{event timeline} -- a minimal but sufficient episodic memory set that can be directly consumed by existing Video-LLMs without additional training or architectural changes.
There are no more articles
❌